<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Despite the large amount of research and reporting on potential biomarkers in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, very few markers have been brought to use in the clinic </plain></SENT>
<SENT sid="1" pm="."><plain>Disorganization plays a large part in this low yield </plain></SENT>
<SENT sid="2" pm="."><plain>The Early Detection Research Network (EDRN) of the National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute has been initiated to foster collaboration among independent institutions/ laboratories to facilitate, standardize, and centralize discovery and validation of candidate biomarkers </plain></SENT>
<SENT sid="3" pm="."><plain>EDRN comprises four components: biomarker reference laboratories; biomarker developmental laboratories; clinical epidemiology and validation centers; and a data management and coordinating center </plain></SENT>
<SENT sid="4" pm="."><plain>Biomarker validation proceeds through five phases-the preclinical exploratory, clinical assay and validation, retrospective longitudinal, prospective screening, and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> control phases </plain></SENT>
<SENT sid="5" pm="."><plain>A number of candidate markers in <z:hpo ids='HP_0003003'>colon cancer</z:hpo>, esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, and <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> (<z:mp ids='MP_0003331'>HCC</z:mp>) currently are moving through the developmental process </plain></SENT>
<SENT sid="6" pm="."><plain>Ongoing EDRN collaborations assessing the potential utility of des-gamma carboxyprothrombin (DCP) in discriminating early <z:mp ids='MP_0003331'>HCC</z:mp> in patients with <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> and the ability of DNA methylation analysis to predict progression from <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> to <z:e sem="disease" ids="C0546837,C0014859" disease_type="Neoplastic Process" abbrv="">esophageal cancer</z:e> are summarized </plain></SENT>
<SENT sid="7" pm="."><plain>EDRN welcomes collaboration in biomarker validation and assembly of sample reference libraries </plain></SENT>
</text></document>